{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:36:20Z","timestamp":1793050580300,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 111-2314-B-002-103-MY2"],"award-info":[{"award-number":["NSTC 111-2314-B-002-103-MY2"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 113-2314-B-400-005"],"award-info":[{"award-number":["NSTC 113-2314-B-400-005"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022294","name":"National Taiwan University Hospital Yunlin Branch","doi-asserted-by":"publisher","award":["NTUHYL112-X021"],"award-info":[{"award-number":["NTUHYL112-X021"]}],"id":[{"id":"10.13039\/501100022294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022294","name":"National Taiwan University Hospital Yunlin Branch","doi-asserted-by":"publisher","award":["NTUHYL112-F009"],"award-info":[{"award-number":["NTUHYL112-F009"]}],"id":[{"id":"10.13039\/501100022294","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Health Research Institute","award":["CG-113-GP-20"],"award-info":[{"award-number":["CG-113-GP-20"]}]},{"name":"National Health Research Institutes","award":["CG-113-GP-05"],"award-info":[{"award-number":["CG-113-GP-05"]}],"id":[{"id":"https:\/\/ror.org\/02r6fpx29","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Taichung Armed Forces General Hospital","award":["TCAFGH_D_114003"],"award-info":[{"award-number":["TCAFGH_D_114003"]}],"id":[{"id":"https:\/\/ror.org\/04nx04y60","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00198-026-08081-8","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:28:35Z","timestamp":1780396115000},"page":"2321-2330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pre-teriparatide anti-osteoporosis medication therapy and fracture-related hospitalization in patients at very high fracture risk"],"prefix":"10.1007","volume":"37","author":[{"given":"Shao-Chi","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chien","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Huei","family":"Sie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chien","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Sen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9853-872X","authenticated-orcid":false,"given":"Shau-Huai","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0498-2438","authenticated-orcid":false,"given":"Chen-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"8081_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Iverg\u00e5rd M et al (2013) Osteoporosis in the European Union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136","journal-title":"Arch Osteoporos"},{"key":"8081_CR2","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s00198-011-1601-6","volume":"22","author":"C Cooper","year":"2011","unstructured":"Cooper C, Cole ZA, Holroyd CR et al (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22:1277\u201388","journal-title":"Osteoporos Int"},{"key":"8081_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrrheum.2009.260","volume":"6","author":"N Harvey","year":"2010","unstructured":"Harvey N, Dennison E, Cooper C (2010) Osteoporosis: impact on health and economics. Nat Rev Rheumatol 6:99\u2013105","journal-title":"Nat Rev Rheumatol"},{"key":"8081_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Norton N, Harvey NC et al (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82","journal-title":"Arch Osteoporos"},{"key":"8081_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40520-021-01817-y","volume":"33","author":"J Barnsley","year":"2021","unstructured":"Barnsley J, Buckland G, Chan PE et al (2021) Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people. Aging Clin Exp Res 33:759\u2013773","journal-title":"Aging Clin Exp Res"},{"key":"8081_CR6","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM et al (2019) Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab 104:1595\u2013622","journal-title":"J Clin Endocrinol Metab"},{"key":"8081_CR7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.20945\/2359-3997000000564","volume":"66","author":"M Chandran","year":"2022","unstructured":"Chandran M (2022) The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence. Arch Endocrinol Metab 66:724\u201338","journal-title":"Arch Endocrinol Metab"},{"issue":"Suppl 1","key":"8081_CR8","first-page":"1","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N et al (2020) College of Endocrinology Clinical Practice guidelines for the diagnosis and treatment of postmenopausal Osteoporosis-2020 update. Endocr Pract American Association of Clinical Endocrinologists\/American 26(Suppl 1):1\u201346","journal-title":"Endocr Pract American Association of Clinical Endocrinologists\/American"},{"issue":"1","key":"8081_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","volume":"12","author":"J Compston","year":"2017","unstructured":"Compston J, Cooper A, Cooper C et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43","journal-title":"Arch Osteoporos"},{"key":"8081_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, McCloskey E et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1\u201312","journal-title":"Osteoporos Int"},{"key":"8081_CR11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa048","volume":"105","author":"D Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM et al (2020) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab 105:dgaa048","journal-title":"J Clin Endocrinol Metab"},{"key":"8081_CR12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the data-switch study): extension of a randomised controlled trial. Lancet 386:1147\u20131155","journal-title":"Lancet"},{"key":"8081_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1359\/jbmr.040117","volume":"19","author":"B Ettinger","year":"2004","unstructured":"Ettinger B, San Martin J, Crans G et al (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745\u2013751","journal-title":"J Bone Miner Res"},{"key":"8081_CR14","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1359\/jbmr.080506","volume":"23","author":"BM Obermayer-Pietsch","year":"2008","unstructured":"Obermayer-Pietsch BM, Marin F, McCloskey EV et al (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23:1591\u20131600","journal-title":"J Bone Miner Res"},{"key":"8081_CR15","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1210\/jc.2007-0711","volume":"93","author":"S Boonen","year":"2008","unstructured":"Boonen S, Marin F, Obermayer-Pietsch B et al (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852\u2013860","journal-title":"J Clin Endocrinol Metab"},{"key":"8081_CR16","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1210\/jc.2008-2719","volume":"94","author":"F Cosman","year":"2009","unstructured":"Cosman F, Wermers RA, Recknor C et al (2009) Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 94:3772\u20133780","journal-title":"J Clin Endocrinol Metab"},{"key":"8081_CR17","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1210\/jc.2008-0353","volume":"93","author":"PD Miller","year":"2008","unstructured":"Miller PD, Delmas PD, Lindsay R et al (2008) Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785\u20133793","journal-title":"J Clin Endocrinol Metab"},{"key":"8081_CR18","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.bone.2007.03.002","volume":"40","author":"R Graham","year":"2007","unstructured":"Graham R, Russell G (2007) Determinants of structure-function relationships among bisphosphonates. Bone 40:S21\u2013S25","journal-title":"Bone"},{"issue":"11","key":"8081_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.43899","volume":"7","author":"CC Lee","year":"2024","unstructured":"Lee CC, Wang CY, Yen HK et al (2024) Zoledronate sequential therapy after denosumab discontinuation to prevent bone mineral density reduction: a randomized clinical trial. JAMA Netw Open 7(11):e2443899. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.43899","journal-title":"JAMA Netw Open"},{"key":"8081_CR20","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/joim.13354","volume":"290","author":"SH Fu","year":"2021","unstructured":"Fu SH, Wang CY, Hung CC et al (2021) Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: a population-based cohort study. J Intern Med 290:1194\u2013205","journal-title":"J Intern Med"},{"key":"8081_CR21","volume":"26","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab 26:dgaa756","journal-title":"J Clin Endocrinol Metab"},{"key":"8081_CR22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3803\/EnM.2021.1369","volume":"37","author":"WL Tay","year":"2022","unstructured":"Tay WL, Tay D (2022) Discontinuing denosumab: can it be done safely? A review of the literature. Endocrinol Metab (Seoul) 37:183\u2013194","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"391","key":"8081_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"20","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 20(391):230\u2013240","journal-title":"Lancet"},{"key":"8081_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.115150","volume":"130","author":"L Tripto-Shkolnik","year":"2020","unstructured":"Tripto-Shkolnik L, Fund N, Rouach V et al (2020) Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider. Bone 130:115150","journal-title":"Bone"},{"key":"8081_CR25","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","volume":"37","author":"F Cosman","year":"2022","unstructured":"Cosman F, Huang S, McDermott M et al (2022) Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses. J Bone Miner Res 37:2112\u201320","journal-title":"J Bone Miner Res"},{"key":"8081_CR26","doi-asserted-by":"crossref","unstructured":"Makras P, Appelman-Dijkstra NM, Papapoulos SE et al (2021) The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation. J Clin Endocrinol Metab\u00a0 106:e4155\u201362-e4162","DOI":"10.1210\/clinem\/dgab321"},{"key":"8081_CR27","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00198-024-07139-9","volume":"35","author":"S Kumar","year":"2024","unstructured":"Kumar S, Gild ML, McDonald MM et al (2024) A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis. Osteoporos Int 35:1669\u201375. https:\/\/doi.org\/10.1007\/s00198-024-07139-9","journal-title":"Osteoporos Int"},{"key":"8081_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae016","volume":"8","author":"G Adami","year":"2024","unstructured":"Adami G, Pedrollo E, Rossini M et al (2024) Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study. JBMR Plus 8:ziae016. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae016","journal-title":"JBMR Plus"},{"issue":"173","key":"8081_CR29","doi-asserted-by":"publisher","first-page":"516","DOI":"10.7326\/M20-0882","volume":"6","author":"H Lyu","year":"2020","unstructured":"Lyu H, Yoshida K, Zhao SS et al (2020) Delayed denosumab injections and fracture risk among patients with osteoporosis: a population-based cohort study. Ann Intern Med 6(173):516\u2013526","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"8081_CR30","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1002\/jbmr.3107","volume":"31","author":"E Seeman","year":"2016","unstructured":"Seeman E, Zebaze R, Zanchetta JR et al (2016) Bone microarchitecture after discontinuation of denosumab in postmenopausal women with low bone mass. J Bone Miner Res 31(Suppl 1):S1-411. https:\/\/doi.org\/10.1002\/jbmr.3107","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08081-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08081-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08081-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:02:54Z","timestamp":1793048574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08081-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8081"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08081-8","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Research Ethics Committee of the National Taiwan University Hospital approved the study protocol (NTUH-REC-202401096 W) and waived the requirement for informed consent.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors had full access to all the data and had final responsibility for the decision to submit for publication. Shao-Chi Fu, Yi-Chien Lu, Ning-Huei Sie, Chih-Chien Hung, Chung-Yi Li, Rong-Sen Yang, Shau-Huai Fu, and Chen-Yu Wang declare that they have no conflict of interest.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}